Reata Pharmaceuticals (RETA)
RETA
Rare Disease
BiotechSign Signal Grade
F
Signal Grade
1.2/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
0
Pipeline Overview
- Therapeutic Focus
- Rare Diseasesrc
Clinical Trial Activity
0
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
5
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- 2000-2025: Emerging therapies in primary mitochondrial disease: A structured review, horizon scan, and roadmap for the future. — Ther Adv Rare Dis 2026 Jan-Dec PMID 42630618
- Neurological effects of encapsulated dexamethasone sodium phosphate in children aged 6-9 years with ataxia telangiectasia (NEAT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. — Lancet Child Adolesc Health 2026 Oct PMID 42600624
- Development of a Virtual Transition Program for Adolescents and Young Adults With Type 1 Diabetes: Three-Stage User-Centered Design Study. — JMIR Pediatr Parent 2026 Jul 16 PMID 42461963
- Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II. — Leukemia 2026 Sep PMID 42410207
- Effects of anti-inflammatory agents on cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials. — Am J Prev Cardiol 2026 Jun PMID 42291081
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Reata Pharmaceuticals.
Full RETA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.